摘要
目的探讨经导管肝动脉化疗栓塞术联合仑伐替尼及替雷利珠单抗治疗原发性肝癌的效果及对血清甲胎蛋白(AFP)水平的影响。方法选取2020年1月至2023年12月该院收治的102例原发性肝癌患者作为研究对象,采用随机数字表法将其分为对照组和联合组,每组51例。2组患者均先给予常规治疗,对照组给予仑伐替尼+替雷利珠单抗治疗,联合组给予经导管肝动脉化疗栓塞术+仑伐替尼+替雷利珠单抗治疗。2组均连续治疗3个月,比较两组患者治疗前、治疗3个月后临床疗效以及血清甲胎蛋白(AFP)、免疫功能相关指标[CD3^(+)、CD4^(+)、CD8^(+)]、肝功能相关指标[血清总胆红素(TBIL)、丙氨酸转氨酶(ALT)]水平。结果联合组总有效率为80.39%,高于对照组的62.75%,差异有统计学意义(χ^(2)=0.048,P<0.05)。治疗后,2组血清AFP、ALT、TBIL水平低于治疗前,且联合组治疗后血清AFP、ALT、TBIL水平低于对照组,差异均有统计学意义(P<0.05)。治疗后,治疗后,2组CD3^(+)、CD4^(+)水平及CD4^(+)/CD8^(+)高于治疗前,而CD8^(+)水平低于治疗前,差异均有统计学意义(P<0.05);联合组治疗后的CD3^(+)、CD4^(+)水平及CD4^(+)/CD8^(+)高于对照组,而CD8^(+)水平低于对照组,差异均有统计学意义(P<0.05)。结论经导管肝动脉化疗栓塞术联合仑伐替尼和替雷利珠单抗治疗原发性肝癌效果较好,值得临床推广应用。
Objective To explore the effect of transcatheter hepatic arterial chemoembolization combined with lenvatinib and tislelizumab in treating primary liver cancer and its impact on serum AFP level.Methods A total of 102 patients with primary liver cancer admitted to the hospital from January 2020 to December 2023 were selected as the research subjects,who were divided into the control group and the combination group by the random number table method,51 cases in each group.Both groups received conventional therapy initially.The control group was treated with lenvatinib+tislelizumab,the combination group was treated with transcatheter hepatic artery chemoembolization,lenvatinib and trastuzumab.Both groups were treated continuously for 3 months,and the clinical efficacy,serum AFP level,immune function related indicators(CD3^(+),CD4^(+),CD8^(+))and liver function related indicators[serum total bilirubin(TBIL),alanine aminotransferase(ALT)]levels were compared between the two groups before and after treatment for 3 months.Results The total effective rate of the combination group was 80.39%,which was higher than 62.75%of the control group,and the difference was statistically significant(χ^(2)=0.048,P<0.05).After treatment,the serum AFP,ALT and TBIL levels in the control group and the combination group were lower than those before treatment,and the levels of serum AFP,ALT,and TBIL in the combination group after treament were lower than those in the control group,with statistically significant differences(P<0.05).After treatment,the CD3^(+),CD4^(+)levels and CD4^(+)/CD8^(+)in both groups were higher than before treatment,while the CD8^(+)level was lower than that before treatment,and the differences had statisticall significance(P<0.05);the CD3^(+),CD4^(+)levels and CD4^(+)/CD8^(+)in the combination group after treatment were higher than those in the control group,while the CD8^(+)level was lower than that in the control group,and the differences had statisticall significance(P<0.05).Conclusion Transcatheter hepatic arterial chemoembolization combined with lenvatinib and tislelizumab is effective in treating primary liver cancer,and it is worthy of clinical promotion and application.
作者
黄洪华
徐爱兵
田思源
徐虎
葛方红
HUANG Honghua;XU Aibing;TIAN Siyuan;XU Hu;GE Fanghong(Department of Intervention,Nantong Tumor Hospital,Nantong,Jiangsu 226361,China;Department of Radiotherapy,Nantong Tumor Hospital,Nantong,Jiangsu 226361,China)
出处
《检验医学与临床》
2025年第20期2835-2839,共5页
Laboratory Medicine and Clinic
基金
江苏省南通市卫生健康委员会指导性课题项目(MSZ2023035)。
关键词
经导管肝动脉化疗栓塞术
仑伐替尼
替雷利珠
原发性肝癌
甲胎蛋白
免疫功能
肝功能
transcatheter hepatic arterial chemoembolization
lenvatinib
tislelizumab
primary liver cancer
alpha fetoprotein
immune function
liver function
